300 related articles for article (PubMed ID: 31099498)
21. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
[TBL] [Abstract][Full Text] [Related]
22. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M
Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Retinal Layer Thickness in Eyes with Resolved Diabetic Macular Edema Receiving Ranibizumab with Normal Eyes.
Rentiya ZS; Kherani S; Usmani B; Qazi MA; Sadiq MA; Iftikhar M; Nguyen QD; Shah SM; Sepah YJ;
Ophthalmologica; 2020; 243(1):27-36. PubMed ID: 31747663
[TBL] [Abstract][Full Text] [Related]
25. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
Mikhail M; Stewart S; Seow F; Hogg R; Lois N
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
[TBL] [Abstract][Full Text] [Related]
26. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.
Hsieh YT; Alam MN; Le D; Hsiao CC; Yang CH; Chao DL; Yao X
Ophthalmol Retina; 2019 Oct; 3(10):826-834. PubMed ID: 31227330
[TBL] [Abstract][Full Text] [Related]
27. Flare levels after intravitreal injection of ranibizumab, aflibercept, or triamcinolone acetonide for diabetic macular edema.
Morioka M; Takamura Y; Yamada Y; Matsumura T; Gozawa M; Inatani M
Graefes Arch Clin Exp Ophthalmol; 2018 Dec; 256(12):2301-2307. PubMed ID: 30238189
[TBL] [Abstract][Full Text] [Related]
28. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
29. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
30. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
31. Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
Barakat MR; Wykoff CC; Gonzalez V; Hu A; Marcus D; Zavaleta E; Ciulla TA
Ophthalmol Retina; 2021 Jan; 5(1):60-70. PubMed ID: 32829027
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
[TBL] [Abstract][Full Text] [Related]
33. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features.
Hatz K; Ebneter A; Tuerksever C; Pruente C; Zinkernagel M
Ophthalmologica; 2018; 239(4):205-214. PubMed ID: 29402873
[TBL] [Abstract][Full Text] [Related]
34. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).
Stefanickova J; Cunha-Vaz J; Ulbig M; Pearce I; Fernández-Vega Sanz A; Theodossiadis P; Kodjikian L; Izmailov A; Muston D; Vassilev Z; Lamotte B; Tückmantel C; Friedl S; Altemark A; Schwarz HJ; Katz T;
Acta Ophthalmol; 2018 Dec; 96(8):e942-e949. PubMed ID: 29696809
[TBL] [Abstract][Full Text] [Related]
35. Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema.
Podkowinski D; Orlowski-Wimmer E; Zlabinger G; Pollreisz A; Mursch-Edlmayr AS; Mariacher S; Ring M; Bolz M
Acta Ophthalmol; 2020 Jun; 98(4):e407-e415. PubMed ID: 31736269
[TBL] [Abstract][Full Text] [Related]
36. Predictive imaging biomarkers relevant for functional and anatomical outcomes during ranibizumab therapy of diabetic macular oedema.
Gerendas BS; Prager S; Deak G; Simader C; Lammer J; Waldstein SM; Guerin T; Kundi M; Schmidt-Erfurth UM
Br J Ophthalmol; 2018 Feb; 102(2):195-203. PubMed ID: 28724636
[TBL] [Abstract][Full Text] [Related]
37. The effect of posterior vitreous detachment on aflibercept response in diabetic macular oedema.
Özsaygili C; Küçük B; Yildirim Y
Br J Ophthalmol; 2021 Jun; 105(6):800-805. PubMed ID: 32727727
[TBL] [Abstract][Full Text] [Related]
38. Relationship Between Final Visual Acuity and Optical Coherence Tomography Findings in Patients with Diabetic Macular Edema Undergoing Anti-VEGF Therapy.
Eraslan S; Yıldırım Ö; Dursun Ö; Dinç E; Orekici Temel G
Turk J Ophthalmol; 2020 Jun; 50(3):163-168. PubMed ID: 32631004
[TBL] [Abstract][Full Text] [Related]
39. Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy.
Huang CH; Yang CH; Hsieh YT; Yang CM; Ho TC; Lai TT
Sci Rep; 2021 Mar; 11(1):5103. PubMed ID: 33658601
[TBL] [Abstract][Full Text] [Related]
40. Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema.
Felfeli T; Juncal VR; Hillier RJ; Mak MYK; Wong DT; Berger AR; Kohly RP; Kertes PJ; Eng KT; Boyd SR; Altomare F; Giavedoni LR; Muni RH
Am J Ophthalmol; 2019 Oct; 206():176-183. PubMed ID: 30959004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
